FT. MYERS, Fla.,
Jan. 12, 2011
/PRNewswire/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it has completed a
equity financing transaction. Five members of the Company's Board of Directors and senior management team and two existing institutional investors of the Company participated in the transaction. The transaction was priced at
per share and resulted in 2.0 million shares of new common stock being issued by the Company. No warrants were issued and no placement agent was used in the transaction. The Company plans to use the proceeds to strengthen its financial position and fund growth initiatives.
, the Company's Chairman and CEO, said the following, "We are very pleased to announce this transaction. The fact that insiders and existing institutional shareholders are willing to purchase shares of restricted stock at a premium to the recent trading price shows our faith in the future prospects of the Company. All of us feel that even at a premium, NeoGenomics is an excellent investment opportunity."
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in
Fort Myers, FL
, NeoGenomics has labs in
and services the needs of pathologists, oncologists, urologists, and hospitals throughout
the United States
. For additional information about NeoGenomics, visit
For more news and information on NeoGenomics, please visit
where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at
or from the American Microcap Institute at
SOURCE NeoGenomics, Inc.